- Home
- BOLD vs XTNT Comparison
BOLD vs XTNT Comparison
Compare BOLD & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- XTNT
- Stock Information
- Founded
- BOLD 2018
- XTNT N/A
- Country
- BOLD United States
- XTNT United States
- Employees
- BOLD N/A
- XTNT N/A
- Industry
- BOLD
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BOLD
- XTNT Health Care
- Exchange
- BOLD Nasdaq
- XTNT Nasdaq
- Market Cap
- BOLD 54.9M
- XTNT 55.6M
- IPO Year
- BOLD 2024
- XTNT N/A
- Fundamental
- Price
- BOLD $2.65
- XTNT $0.43
- Analyst Decision
- BOLD Buy
- XTNT Strong Buy
- Analyst Count
- BOLD 3
- XTNT 1
- Target Price
- BOLD $22.50
- XTNT $3.00
- AVG Volume (30 Days)
- BOLD 143.3K
- XTNT 212.2K
- Earning Date
- BOLD 11-07-2024
- XTNT 11-12-2024
- Dividend Yield
- BOLD N/A
- XTNT N/A
- EPS Growth
- BOLD N/A
- XTNT N/A
- EPS
- BOLD N/A
- XTNT N/A
- Revenue
- BOLD N/A
- XTNT $113,862,000.00
- Revenue This Year
- BOLD N/A
- XTNT $31.82
- Revenue Next Year
- BOLD N/A
- XTNT $13.64
- P/E Ratio
- BOLD N/A
- XTNT N/A
- Revenue Growth
- BOLD N/A
- XTNT 45.11
- 52 Week Low
- BOLD $2.33
- XTNT $0.33
- 52 Week High
- BOLD $15.24
- XTNT $1.31
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- XTNT 60.37
- Support Level
- BOLD N/A
- XTNT $0.33
- Resistance Level
- BOLD N/A
- XTNT $0.39
- Average True Range (ATR)
- BOLD 0.00
- XTNT 0.03
- MACD
- BOLD 0.00
- XTNT 0.01
- Stochastic Oscillator
- BOLD 0.00
- XTNT 88.68
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.